Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

New research reveals music's health benefits

Music has been incorporated into medical practice since before the ancient Greeks. However, though practitioners have been convinced of music's health benefits for thousands of years, there had been little peer-reviewed research to back them up. But recent studies are providing an empirical backbone for the anecdotal evidence.

17 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Heart-healthy diet may reduce recurrent stroke, MI risk

Eating a “heart-healthy” diet may lower the risk for recurrent cardiovascular disease events in middle-aged individuals with a history of such conditions, researchers report.

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

RedHill Biopharma completes $6.5M private placement

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.

6 Dec 2012

Healthy eating prevents second heart attack, stroke or death in people with CVD

A heart-healthy diet rich in fruits, vegetables and fish significantly reduces the chance of a second heart attack and stroke in people with cardiovascular disease, McMaster University researchers have found.

4 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Ginger.io announces $6.5M Series A funding

Ginger.io, the behavioral health analytics startup, today announced a $6.5 million Series A funding round led by Khosla Ventures.

29 Nov 2012

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.

22 Nov 2012

Facts about Homecare

Millions of seniors and people living with disabilities will enjoy Thanksgiving and other holidays in the comfort and safety of their own homes thanks to home medical equipment and services such as oxygen therapy, hospital beds, and wheelchairs.

21 Nov 2012

Sociologic factors predict time to discharge in lower limb amputees

Sociologic factors such as marital status and living location before hospitalization are key predictors of time to discharge in male veterans after lower extremity amputation, report researchers.

20 Nov 2012

Neurologist care lowers risk for PD-related hospitalizations

Regular care by a neurologist lowers the risk for hospitalization for Parkinson's disease-related complications, US research shows.

20 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

Cardiovascular disease will kill nearly 2.5 million people in the United States this year, according to the Centers for Disease Control. Over time, inflammation, collagen deposition and scar tissue formation can cause blood vessels to stiffen, a process called vascular fibrosis. Though researchers have known that the hormone aldosterone (Aldo) plays a role in this process, the precise mechanisms have been poorly understood.

17 Nov 2012

Simple biomarker model to predict heart failure risk

The most widely used models for predicting heart failure rely on a complex combination of lifestyle, demographic, and cardiovascular risk factor information.

8 Nov 2012

Study highlights value of specialized care in heart failure treatment

When a cardiologist attends to heart failure patients, even when the severity of illness is higher, patients have reduced rates of hospital readmissions, compared with those patients who are treated by a hospitalist, according to a trial being presented today at the American Heart Association's scientific sessions in Los Angeles.

7 Nov 2012

Paragonix files PMNA with FDA for Sherpa Pak Cardiac Transport System

Paragonix Technologies, Inc. today announced that it has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its Paragonix Sherpa Pak Cardiac Transport System (CTS).

6 Nov 2012

Lifetime risks for total CVD are high regardless of index age

Even in men and women with an optimal cardiovascular disease (CVD) risk factor profile, the lifetime risk estimate for CVD is greater than 30 percent, and is more than 50 percent for men and women overall, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease.

6 Nov 2012

Keeping cardiovascular disease risk factors low may lead to a longer, healthier life

If you have optimal heart health in middle age, you may live up to 14 years longer, free of cardiovascular disease, than your peers who have two or more cardiovascular disease (CVD) risk factors, according to a new Northwestern Medicine study.

6 Nov 2012

No link between daily multivitamin use and reduction of major cardiovascular events in men

In a randomized study that included nearly 15,000 male physicians who were middle-aged or older, daily multivitamin use for more than 10 years of treatment and follow-up did not result in a reduction of major cardiovascular events, heart attack, stroke, or death from cardiovascular disease, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease.

5 Nov 2012

Congestive Heart Failure News and Research

New research reveals music's health benefits

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Heart-healthy diet may reduce recurrent stroke, MI risk

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

RedHill Biopharma completes $6.5M private placement

Healthy eating prevents second heart attack, stroke or death in people with CVD

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Ginger.io announces $6.5M Series A funding

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

Facts about Homecare

Sociologic factors predict time to discharge in lower limb amputees

Neurologist care lowers risk for PD-related hospitalizations

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

Simple biomarker model to predict heart failure risk

Study highlights value of specialized care in heart failure treatment

Paragonix files PMNA with FDA for Sherpa Pak Cardiac Transport System

Lifetime risks for total CVD are high regardless of index age

Keeping cardiovascular disease risk factors low may lead to a longer, healthier life

No link between daily multivitamin use and reduction of major cardiovascular events in men

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News